Table 2. Comorbidities and drug treatment.
| Total (n = 276) | Group 1 | Group 2 | P | |
| Comorbidity | ||||
| Hypertension | 255 (92) | 125 (91) | 130 (94) | NS |
| Dyslipidemia | 260 (94) | 131 (95) | 129 (94) | NS |
| Type 2 diabetes | 147 (53) | 72 (52) | 75 (54) | NS |
| Obesity | 144 (55) | 62 (47) | 82 (63) | 0.01 |
| Smoke | 64 (23) | 33 (24) | 31 (23) | NS |
| Leriche/Fontaine | ||||
| I | 146 (53) | 84 (61) | 62 (45) | 0.013 |
| IIA | 78 (28) | 36 (26) | 42 (30) | |
| IIB | 52 (19) | 18 (13) | 34 (25) | |
| Drug therapy | ||||
| ARBs | 108 (39) | 49 (36) | 59 (43) | NS |
| ACE inhibitors | 107 (39) | 47 (34) | 60 (44) | NS |
| Calcium channel blockers | 85 (31) | 42 (30) | 43 (31) | NS |
| β-blockers | 73 (26) | 36 (26) | 37 (27) | NS |
| Diuretics | 119 (43) | 45 (33) | 74 (54) | < 0.001 |
| Anti-platelet | 238 (86) | 119 (86) | 119 (86) | NS |
| Statin | 242 (88) | 123 (89) | 119 (86) | NS |
| Allopurinol and/or febuxostat* | 29 (11) | 17 (12) | 12 (9) | NS |
| Anti-diabetic therapy | ||||
| Diet | 46 (31) | 21 (29) | 25 (34) | 0.048 |
| Oral hypoglycemic | 68 (46) | 40 (56) | 28 (37) | |
| Insulin + oral hypoglycemic | 33 (23) | 11 (15) | 22 (29) |
Data are presented as n (%). *Only one patient was treated by febuxostat. ACE inhibitors: angiotensin converting enzyme inhibitors; ARBs: angiotensin receptor blockers; NS: not significant.